Skip to main
OPK
OPK logo

OPKO Health (OPK) Stock Forecast & Price Target

OPKO Health (OPK) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

OPKO Health's recent divestiture of select laboratory testing businesses to Labcorp is viewed positively as it strategically refocuses the company on its drug development capabilities, thereby strengthening its balance sheet. The transaction is anticipated to enhance efficiencies within BioReference’s operations, positioning it for improved profitability, especially compared to the less profitable clinical diagnostics assets previously divested. Overall, this move, along with others, suggests a clear pathway for OPKO to optimize its resources and enhance its financial stability going forward.

Bears say

The negative outlook on OPKO Health's stock is driven by several key risks that could impede its financial performance. These include the potential for lower-than-expected growth in its diagnostics services, challenges in developing and obtaining regulatory approval for new pharmaceuticals, and fluctuating sales in emerging markets compounded by foreign exchange rate volatility. Additionally, the company faces significant competitive pressures and potential dilution risks, which could affect its market penetration and overall commercial success.

OPKO Health (OPK) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OPKO Health (OPK) Forecast

Analysts have given OPKO Health (OPK) a Buy based on their latest research and market trends.

According to 11 analysts, OPKO Health (OPK) has a Buy consensus rating as of Sep 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OPKO Health (OPK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.